IL240787B - Mimetics of apoflavon and their uses - Google Patents

Mimetics of apoflavon and their uses

Info

Publication number
IL240787B
IL240787B IL240787A IL24078715A IL240787B IL 240787 B IL240787 B IL 240787B IL 240787 A IL240787 A IL 240787A IL 24078715 A IL24078715 A IL 24078715A IL 240787 B IL240787 B IL 240787B
Authority
IL
Israel
Prior art keywords
apolipoprotein mimetics
apolipoprotein
mimetics
Prior art date
Application number
IL240787A
Other languages
English (en)
Hebrew (he)
Other versions
IL240787A0 (en
Original Assignee
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Res Found filed Critical Uab Res Found
Publication of IL240787A0 publication Critical patent/IL240787A0/en
Publication of IL240787B publication Critical patent/IL240787B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL240787A 2013-03-14 2015-08-24 Mimetics of apoflavon and their uses IL240787B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US201361834992P 2013-06-14 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Publications (2)

Publication Number Publication Date
IL240787A0 IL240787A0 (en) 2015-10-29
IL240787B true IL240787B (en) 2019-07-31

Family

ID=51581312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240787A IL240787B (en) 2013-03-14 2015-08-24 Mimetics of apoflavon and their uses

Country Status (12)

Country Link
US (1) US20160002315A1 (enExample)
EP (1) EP2996706B1 (enExample)
JP (2) JP6570511B2 (enExample)
AU (2) AU2014239186B2 (enExample)
BR (1) BR112015022624A2 (enExample)
CA (1) CA2903869A1 (enExample)
DK (1) DK2996706T3 (enExample)
ES (1) ES2753381T3 (enExample)
IL (1) IL240787B (enExample)
MX (1) MX2015012818A (enExample)
NZ (1) NZ713291A (enExample)
WO (1) WO2014152776A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
MA44234B1 (fr) * 2016-02-17 2023-10-31 Regeneron Pharma Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
EA201891979A1 (ru) 2016-03-03 2019-01-31 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3
WO2023018876A2 (en) * 2021-08-11 2023-02-16 The Regents Of The University Of California Barrier function preserving peptides for membranes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
CA2697957A1 (en) * 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CN102917727B (zh) * 2010-01-06 2017-10-17 康石医药科技(上海)有限公司 Apoe肽及其用途
CA2954475C (en) * 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Also Published As

Publication number Publication date
AU2017203911A1 (en) 2017-06-29
ES2753381T3 (es) 2020-04-08
EP2996706A4 (en) 2017-01-18
EP2996706B1 (en) 2019-07-31
US20160002315A1 (en) 2016-01-07
EP2996706A1 (en) 2016-03-23
AU2014239186B2 (en) 2017-04-20
WO2014152776A1 (en) 2014-09-25
DK2996706T3 (da) 2019-10-21
CA2903869A1 (en) 2014-09-25
JP6772317B2 (ja) 2020-10-21
JP6570511B2 (ja) 2019-09-04
NZ713291A (en) 2017-04-28
AU2014239186A1 (en) 2015-10-08
AU2017203911B2 (en) 2019-03-07
MX2015012818A (es) 2016-05-12
JP2019089834A (ja) 2019-06-13
BR112015022624A2 (pt) 2017-10-31
JP2016515137A (ja) 2016-05-26
IL240787A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
IL274355B (en) Aza-pyridone compounds and their uses
GB201317286D0 (en) Composition and Use
GB201323008D0 (en) Compounds and uses thereof
GB201305277D0 (en) Novel combination and use
PT3058936T (pt) Composição peptídica e respetivos usos
GB201321693D0 (en) Composition and uses thereof
EP2933176A4 (en) ROLLING BOARD ELEMENT AND SKATEBOARD COMPRISING THE SAME
IL240248A0 (en) Met-binding substances and their uses
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL243433B (en) Titanium bibory layers and their production
LT3087092T (lt) Antimikrobinis peptidas ir jo panaudojimas
GB201307233D0 (en) Compounds and uses thereof
IL240787B (en) Mimetics of apoflavon and their uses
EP3041028A4 (en) LAMINATE AND ITS APPLICATION
GB201309178D0 (en) Enzyme and uses thereof
GB201307989D0 (en) Novel combinations and use
GB201320992D0 (en) Complex and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201305297D0 (en) Novel agents and uses thereof
GB201301022D0 (en) Composition and uses thereof
GB201301393D0 (en) Kiddibidet and pottibidet

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed